Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Troglitazone-induced changes in adiponectin do not affect endothelial function in diabetes.

Jon Buras1, Wende R Reenstra, Daniel Orlow

  • 1Microcirculation Laboratory, Palmer 317, West Campus, Beth Israel Deaconess Medical Center, One Deaconess Road, Boston, MA 02215, USA.

Obesity Research
|August 4, 2005
PubMed
Summary

Troglitazone treatment increased adiponectin levels in type 2 diabetic patients but did not improve endothelium-dependent vasodilation. This suggests adiponectin may not be a key factor in endothelial function.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MIAAIM: Multi-omics image integration with dimensional reduction for tissue state mapping.

PLoS computational biology·2026
Same author

Intelligent In situ Printing of Multimaterial Bioinks for First-Aid Wound Care Guided by Eye-In-Hand Robot Technology.

Advanced materials technologies·2025
Same author

Microcirculation of the Diabetic Foot.

Clinics in podiatric medicine and surgery·2025
Same author

Integrated machine learning analysis of proteomic and transcriptomic data identifies healing associated targets in diabetic wound repair.

Scientific reports·2025
Same author

Management of Diabetic Wounds: Expert Panel Consensus Statement.

Advances in wound care·2025
Same author

Effect of continuous positive airway pressure on ventricular remodeling of patients with combined diabetes mellitus and obstructive sleep apnea: a cross-sectional study and follow-on randomized clinical trial.

International journal of cardiology·2025

Area of Science:

  • Endocrinology
  • Cardiovascular Research
  • Metabolic Syndrome

Background:

  • Adiponectin is an adipokine linked to endothelial function.
  • Troglitazone treatment can increase adiponectin levels.
  • The impact of troglitazone-induced adiponectin increase on endothelial function in type 2 diabetes requires investigation.

Purpose of the Study:

  • To investigate the relationship between elevated adiponectin levels due to troglitazone and endothelium-dependent vasodilation in type 2 diabetic patients.
  • To assess the effect of troglitazone on vascular reactivity and endothelial activation markers.

Main Methods:

  • A randomized, placebo-controlled, double-blinded study involving 72 type 2 diabetic patients.
  • High-resolution ultrasound to measure brachial artery flow-mediated dilation (endothelium-dependent) and nitroglycerin-induced dilation (endothelium-independent).

Related Experiment Videos

  • Laser Doppler perfusion imaging for forearm skin vascular reactivity assessment.

    • Main Results:

    • Troglitazone treatment increased adiponectin levels by 75% but did not alter endothelium-dependent vasodilation or other vascular reactivity measures.
    • No significant changes were observed in endothelial activation markers or skin receptor for advanced glycation end-products expression.
    • Adiponectin levels correlated with changes in fasting plasma glucose, hemoglobin A1c, total cholesterol, and LDL-cholesterol.

    Conclusions:

    • The increase in adiponectin levels following troglitazone treatment is not associated with improved endothelium-dependent vasodilation in type 2 diabetic patients.
    • Adiponectin does not appear to be a major determinant of endothelial function in this context.
    • Troglitazone treatment did not affect receptor for advanced glycation end-products expression in the skin microcirculation.